Loading...
01/11 17:51
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals mixed signals. While there are positive aspects such as improved net loss, increased service revenue, and strategic product launches, there are concerns about declining revenue, lower gross margins, and uncertainties in academic funding. The Q&A highlights management's cautious optimism, with no clear guidance on macroeconomic impacts. Despite some positive product developments, the overall sentiment remains neutral due to the lack of strong financial performance and clear guidance. The market's reaction is likely to be muted, resulting in a neutral stock price movement.
Revenue for Q2 2025 $45.6 million, down $1 million or 2.2% compared to Q2 2024. The decrease was due to lower product revenue in EMEA and APAC, partially offset by strong growth in service revenue worldwide (18%) and growth in U.S. product revenue.
Service and Reagent Revenue Each increased by 18% versus Q2 2024. Growth was driven by the established and expanding installed instrument base.
Recurring Revenue Reached 32% of trailing 12-month sales in Q2 2025, growing 16% year-over-year. Growth was supported by the installed instrument base and recurring revenue streams.
FSP Unit Volume Grew 3% in Q2 2025, led by Aurora Analyzers. U.S. showed 10% year-over-year growth, indicating strong core business performance.
U.S. Revenue Increased 7% in Q2 2025 compared to Q2 2024, driven by service and reagents. Instrument sales were flat due to offsetting growth in pharma, biotech, and CRO customers and softness among academic and government customers.
EMEA Revenue Declined 11% in Q2 2025 due to weakness in instrument sales to pharma, biotech, and CRO customers, offset by growth among academic and government customers and in service and reagents.
APAC Revenue Declined in Q2 2025 following strong Q1 performance, primarily due to longer sales cycles in the region. However, the region showed solid long-term growth.
Rest of World Revenue Delivered single-digit percentage growth in Q2 2025 compared to Q2 2024.
First Half 2025 Revenue Down 5% compared to the first half of 2024. Weakness in EMEA (down 17%) and U.S. (down 3%) was partially offset by growth in APAC (up 9%) and Rest of World (up 14%).
Gross Profit Margin (GAAP) 52% in Q2 2025, down from 55% in Q2 2024. Decline was due to lower product gross margin and increased material costs.
Adjusted Gross Profit Margin 56% in Q2 2025, down from 58% in Q2 2024. Improvement from Q1 2025 (52%) due to higher product gross margins and lower manufacturing overhead.
Operating Expenses $34.5 million in Q2 2025, up 2% compared to Q2 2024. Increase was driven by higher general and administrative expenses.
Net Loss $5.6 million in Q2 2025, compared to $10.4 million in Q2 2024. Improvement was due to increased net other income and a tax benefit.
Adjusted EBITDA $1.3 million in Q2 2025, down from $2.9 million in Q2 2024, due to lower gross profit.
Free Cash Flow Positive $0.9 million in Q2 2025, offset by $4.5 million in share repurchases.
Aurora Evo System: Launched as an enhancement to the flagship Aurora Cell Analyzer, offering faster sample throughput, automated instrument startup and shutdown, small particle detection, and data harmonization.
Cytek Cloud: Continued growth with over 20,500 users as of June 30, 2025, representing a 27% increase since the beginning of the year. It simplifies complex flow cytometry experiments and drives adoption of Cytek's technology.
Global Instrument Expansion: Added 146 instruments in Q2, bringing the total installed base to 3,295 units. Aurora Analyzer was the strongest driver of unit growth.
Geographic Revenue Performance: U.S. revenue grew 7% in Q2, while EMEA and APAC saw declines of 11% and 12%, respectively. Rest of World region showed single-digit growth.
Recurring Revenue Growth: Service and reagent revenue each increased by 18% in Q2 2025 compared to Q2 2024. Recurring revenue businesses now account for 32% of trailing 12-month sales.
Reagent Operations: Significant improvements in reagent operations led to shorter delivery times and double-digit sales growth in the U.S., EMEA, and China.
Strategic Pillars: Focused on instruments, applications, bioinformatics, and clinical solutions to solidify market leadership in next-gen cell analysis.
Reagent Market Potential: Estimated $150 million annual reagent consumption by the installed base, with current revenue capturing less than 10% of this potential.
Revenue Decline: Second quarter revenue in 2025 decreased by 2.2% compared to the same period in 2024, primarily due to lower product revenue in EMEA and APAC regions.
Geographic Revenue Weakness: EMEA revenue declined by 11% due to weak instrument sales to pharma, biotech, and CRO customers. APAC sales also declined following a strong Q1, attributed to longer sales cycles in the region.
Academic and Government Funding Uncertainty: Continued softness in instrument orders from academic and government customers in the U.S. due to uncertainties in academic funding resulting from U.S. policy changes.
Product Revenue Decline: Product revenue, including instruments and reagents, decreased by 9% year-over-year, driven by significant declines in EMEA.
Gross Margin Pressure: GAAP gross profit margin declined to 52% from 55% in the prior year quarter, impacted by lower product revenues and increased material costs.
Operating Loss: Loss from operations increased to $10.6 million in Q2 2025 from $8.5 million in the prior year quarter, driven by lower gross profit and higher operating expenses.
Market Conditions: Challenging capital equipment spending environment, particularly affecting academic and government sectors.
Currency Exchange Risks: Foreign exchange gains and losses have impacted financial results, with $1.6 million in gains this quarter compared to $1.8 million in losses in the prior year.
Longer Sales Cycles in APAC: Sales cycles in the APAC region are longer compared to other regions, contributing to revenue variability.
Policy-Driven Constraints: Policy issues affecting various markets are expected to constrain capital equipment spending through at least Q3 2025.
Full Year 2025 Revenue Guidance: Cytek Biosciences has narrowed its full-year 2025 revenue guidance to a range of $196 million to $205 million, representing overall growth of -2% to +2% over full-year 2024, assuming no change from current currency exchange rates.
Market Recovery Expectations: The company expects the instrument market to recover over time and is positioning itself to emerge in a stronger position when this occurs.
Recurring Revenue Growth: Cytek anticipates long-term sustainable growth in its recurring revenue streams, including service and reagent businesses, driven by the expansion of its installed instrument base.
Reagent Business Growth Potential: The company estimates that its currently installed instrument base consumes at least $150 million worth of reagents annually, with current reagent revenue capturing less than 10% of this potential, indicating substantial room for growth.
Strategic Focus on Innovation: Cytek plans to strengthen its market leadership through innovation, including the launch of the Cytek Aurora Evo system, which is expected to accelerate adoption and create new markets.
Share Repurchase: In the second quarter, Cytek repurchased $4.5 million of its stock, equivalent to 1.2 million shares. For the first half of 2025, the company repurchased $15.1 million worth of stock, totaling 3.3 million shares. This reduced the total shares outstanding to 127.2 million as of June 30, 2025.
The earnings call reveals mixed signals. While there is strong growth potential in the reagent business and a strategic focus on innovation, the financial performance is concerning with a net loss and declining EBITDA. The Q&A highlights positive trends in Asia Pacific and biopharma, but challenges in EMEA and U.S. academic sectors persist. The cautious guidance for 2025 and stable U.S. performance balance the negatives, leading to a neutral sentiment rating.
The earnings call reveals mixed signals. While there are positive aspects such as improved net loss, increased service revenue, and strategic product launches, there are concerns about declining revenue, lower gross margins, and uncertainties in academic funding. The Q&A highlights management's cautious optimism, with no clear guidance on macroeconomic impacts. Despite some positive product developments, the overall sentiment remains neutral due to the lack of strong financial performance and clear guidance. The market's reaction is likely to be muted, resulting in a neutral stock price movement.
The earnings call reveals several negative indicators: declining revenue, gross margins, and increased operating losses. Despite some positive elements like service revenue growth and share repurchases, the overall financial performance is weak. The Q&A highlights uncertainties regarding tariffs and funding, and management's unclear responses further exacerbate concerns. The revised revenue outlook and increased losses suggest potential growth challenges. Combined, these factors indicate a likely negative stock price movement in the short term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
